Sir, the cartoonish characterisations of the current covers of the BDJ [Volume 223, published July-December 2017] serve to diminish the credibility of the contents of the journal and demean the dental profession. For a serious academic journal, more appropriate cover subject matter might portray some of the history of dentistry's rise from barber-surgeons to the current and future status of the profession as a scientificallybased health discipline. Dentistry should not be portrayed in a discreditable comedic manner, with its reputation already much diminished as a cosmetic calling. 
G. Sperber, Canada

T e Editor-in-Chief responds: I thank Professor
Pathetic jokes
Sir, I am writing to you to complain about the content of BDJ Volume 223 No. 12, published on 22 December 2017, which contained inaccurate yet plausible content that could mislead and misinform readers of this journal.
The Editorial set the tone for this edition by reporting the use of robots to perform implants in China. This is within the bounds of possibility as was the next item regarding data transmitted from electronic toothbrushes which could lead to a Home Dental Check system that could determine whether a visit to the dentist was required. There were two other 'developments' that bordered on the edge of believable (Uberdent and Airrotor).
Spoof letters and fake news articles regarding various aspects of Christmas and its relevance to CQC, Christmas cards, whisky, cakes and Russian hacking in BDA elections followed. These were all very tongue in cheek (forgive the pun). There followed what I presumed was the serious part of the journal dealing with electronic records, oral and maxillofacial trauma, and burnout in dental students. My problem with the first (flippant) part of the journal is that I now had to ask myself, 'do I believe that there is burnout in dental students with all the attendant suicide problems or is this one of their jokes?' My feeling, if you have not discerned it so far, is that there is a place for spoof articles and bogus reporting but a serious professional journal is not the forum for such. Anything you read in a professional publication should be true, trusted and believable and not subject to doubt because of some pathetic jokes inserted by the editorial staff. All that was required from the Editor was 'Happy Christmas to all our members and a plague on the GDC' . 
Oral surgery
A helpful wisdom tooth
Sir, we would like to share a rather amusing case involving an extraction technique on a tooth with its own point of application. A patient was admitted for removal of 38 under local anaesthetic in our outpatient department. The tooth was partly erupted but in a fairly vertical position. When a mucoperiosteal flap was raised we noticed a carious cavity buccally which was not visible on the radiograph. Therefore, without the need of bone removal, a Cryer elevator was applied to the cavity as a point of application and the tooth was elevated in a straightforward manner.
In the available literature the drilling of a cavity into a tooth to create an application point during elevation has been described. 1, 2 In our case this tooth already had an appropriately sized buccal cavity created by caries subgingivally and hence no drilling was required (Fig. 1) . The figure reveals a slight distally curved root and the tooth morphology favoured the path of withdrawal of this tooth in a distal direction. With slight rotation of Cryer elevator within the cavity the tooth eventually 'popped out' distally. This enabled the extraction in an atraumatic manner with no bone removal or tooth sectioning required. 
Pharmacology
MRONJ risk factor
Sir, medication-related osteonecrosis of the jaw (MRONJ) is a well-documented complication associated with bone modulating therapy from various bisphosphonates and denosumab. In additional anti-angiogenic medication (tyrosine kinase inhibitors and new biologics including monoclonal antibodies) have also been implicated and hence the list of drugs continues to grow. Once patients are 'at risk' of MRONJ, well established risk factors for development of the complication include dental extractions, smoking, trauma, poor dental health and those who are immunocompromised and immunosuppressed. In this latter group certain medications such as corticosteroids, azathioprine, mycophenolate mofetil and methotrexate have been particularly identified. Leflunomide (Arava) is a disease modifying anti-rheumatic drug (DMARD) that has been used in the treatment of rheumatoid and psoriatic arthritis for many years and can be given in combination with bisphosphonates and methotrexate. In vitro studies indicate that leflunomide selectively inhibits RANK-L-induced differentiation of osteoclast, which in turn directly affects bone remodelling as well as inhibiting several tyrosine kinases. 1 These actions are exactly those targeted by the various implicated MRONJ drugs mentioned earlier.
Leflunomide has not been reported as a MRONJ drug. However, we wish to highlight this drug as a possible candidate to be added to the other immunosuppressants that have already been recognised to increase the risk of MRONJ when taken in conjunction with bone modulating and anti-angiogenic therapy. In our dedicated jaw necrosis clinic, 102 patients have been registered with MRONJ of which only two cases are from oral bisphosphonates. In these two cases one patient had bilateral maxillary MRONJ (alendronic acid two years, leflunomide six years) following dental extraction. In addition to this case a further two cases of methotrexate related jaw necrosis are also being managed. Methotrexate jaw necrosis is very rare and often preceded by lymphoproliferative disorder, however, in both our cases this was absent but both on long-term leflunomide. 2 Of these two cases, one failed to heal post extraction while the other case had spontaneous necrosis in a dentate region.
Leflunomide is not a new drug and in the absence of literature reported cases of osteonecrosis of the jaw directly related to it as well as evidence of its impact on bone, it remains reasonable to consider it as a risk factor for MRONJ along with the other already recognised immunosuppressant when taken concomitantly with those drugs that have been implicated in jaw necrosis. 
No studies
Sir, I wish to congratulate Patel and colleagues for their article 1 in which they evaluated medication-related osteonecrosis of the jaw (MRONJ) in early stage breast cancer. 1 The authors stated that oral clodronate and i.v. zoledronic acid appear to be equally effective in reducing breast cancer recurrence and mortality in the adjuvant setting. However, to date, there are no studies comparing efficacy of oral bisphosphonates with i.v. zoledronic acid in terms of reducing clinical outcome when they are used in breast cancer at adjuvant setting. Furthermore, it is expected that intravenous bisphosphonates could be more effective than oral due to their potentially more anti-tumoral activity. 
